AOC3: Amine oxidase [copper-containing] 3
Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on AOC3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vepalimomab | Phase 2 | — | Antibody | InhibitorAmine oxidase, copper containing inhibitor | 0 |
- Type 2 diabetes mellitus0.27
- Metabolic syndrome0.22
- Neoplasm0.10
- Cancer0.10
- Diabetes mellitus0.09
- Lung carcinoma0.09
- Lung cancer0.08
- Allergic rhinitis0.08
- Experimental autoimmune encephalomyelitis0.08
- Thyroid cancer0.08
- Thyroid gland carcinoma0.08
- Central nervous system cancer0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3437, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q16853, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets